17.11.2004 – 17:46

SYGNIS AG

euro adhoc: LION Bioscience AG
Board of Directors (Appointments and Changes)
Management Board Change

Disclosure announcement transmitted by euro adhoc.
  The issuer is responsible for the content of this announcement.

Cambridge, MA, USA, Heidelberg, Germany, November 17, 2004 - The
Supervisory Board of LION bioscience AG has reappointed LION´s
Executive Board with immediate effect. Dr. Thure Etzold was appointed
Chief Executive Officer (CEO). Peter Willinger, who is head of the
finance department since 1998, was appointed Chief Financial Officer
(CFO). Joseph F. Donahue moves from the Board and remains responsible
for Global Sales and continues to be President of LION bioscience,
Inc, LION’s U.S. subsidiary.

Peter Willinger joined LION in November 1998 as Director Controlling
and served as Vice President Global Finance & Operations since
October 2001. After he received his BA degree in business economics
at the Mannheim University, he worked as a controller for Rudolf Wild
GmbH & Co KG/Heidelberg for eight years.

end of announcement                    euro adhoc 17.11.2004 17:10:37 

Further inquiry note:

Günter Dielmann, Tel.: +49 6221 4038-249,
guenter.dielmann@lionbioscience.com

Julia Fritz, Tel.: +49 6221 4038-158,
julia.fritz@lionbioscience.com

Branche: Pharmaceuticals
ISIN: DE0005043509
WKN: 504350
Index: Nemax 50, Prime Standard, TecDAX
Börsen: Frankfurter Wertpapierbörse / regulated dealing
New York / regulated dealing
Berliner Wertpapierbörse / free trade
Hamburger Wertpapierbörse / free trade
Baden-Württembergische Wertpapierbörse / free trade
Börse Düsseldorf / free trade
Niedersächsische Börse zu Hannover / free trade
Bayerische Börse / free trade
Bremer Wertpapierbörse (BWB) / free trade